



Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMB control number.

Approved for use through 07/31/2006. OMB 0651-0031

Substitute for form 1449A/P TO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sh

12

Attorney Docket Number 44342.018300

Application Number	10/559,155
Filing Date	December 5, 2005
First Named Inventor	K. MIYAZONO
Art Unit	TBB 16014
Examiner Name	TBB TZ HENLEY
Attorney Docket Number	44342.018300

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵
		Country Code ³ "Number" "Kind Code ⁶ (if known)				
<i>[Signature]</i>		WO 2000/61576 A1	10-19-00	Smithkline Beecham	See IPER	
<i>[Signature]</i>		WO 2002/22871 A2	3-21-02	Decode Genetics	See IPER	

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 If possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.
This collection of information is required by 37 CFR 1.87 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

American LegalNet, Inc.
www.USCourtForms.com

Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number.

Substitute for form 1449B/PTO		<i>Complete If Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/559,155
(Use as many sheets as necessary)		Filing Date	December 5, 2005
		First Named Inventor	K. MIYAZONO
		Art Unit	TBD- 1614
		Examiner Name	TBD R. Henley
		Attorney Docket Number	44342.018300

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Kunio TAKAOKA, Tominaga SHIMIZU, "BMP ni yoru Hone Saisei to Kotsu Soshosho," Igaku no Ayumi, <u>2001</u> , Vol. 198, p. 625-629	
		SPINELLA-JAEGLE, S. et al., Opposite effects of bone morphogenetic protein-2 and transforming growth factor-beta1 on osteoblast differentiation, <u>Bone</u> , <u>2001</u> , Vol. 29, No. 4, p. 323-330	
		Shingo MAEDA, Kenji IMAMURA, Kohei MIYAZONO, "TGF- beta/BMP Signal to Kotsuga Saibo Bunka," Experimental Medicine, <u>2002</u> , Vol. 20, no. 17 (Zokan), p. 101-106	
		INMAN, Gareth J. et al., SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7, <u>Molecular Pharmacology</u> , <u>2002</u> , Vol. 62, No. 1, pages 65-74	

Examiner Signature	Karen M. Hays	Date Considered	12/14/06
--------------------	---------------	-----------------	----------

*** EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.
1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.